Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115861303 | 11586130 | 3 | F | 201404 | 20160322 | 20151001 | 20160817 | PER | US-AEGERION PHARMACEUTICALS-AEGR000400 | AEGERION | 67.45 | YR | M | Y | 115.65000 | KG | 20160817 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115861303 | 11586130 | 1 | PS | JUXTAPID | LOMITAPIDE MESYLATE | 1 | Oral | 5 MG, QD | 445 | MG | Y | U | 203858 | 5 | MG | CAPSULE | QD | ||
| 115861303 | 11586130 | 2 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 10 MG, QHS | 1110 | MG | Y | 0 | 10 | MG | QD | ||||
| 115861303 | 11586130 | 3 | C | RANEXA | RANOLAZINE | 1 | Oral | 1000 MG, BID | 1749972.75 | MG | U | 0 | 1000 | MG | |||||
| 115861303 | 11586130 | 4 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | UNK | U | 0 | ||||||||||
| 115861303 | 11586130 | 5 | C | CILOSTAZOL. | CILOSTAZOL | 1 | UNK | U | 0 | ||||||||||
| 115861303 | 11586130 | 6 | C | DOXAZOSIN | DOXAZOSINDOXAZOSIN MESYLATE | 1 | 8 MG, BID | U | 0 | 8 | MG | ||||||||
| 115861303 | 11586130 | 7 | C | JANUVIA | SITAGLIPTIN PHOSPHATE | 1 | UNK | U | 0 | ||||||||||
| 115861303 | 11586130 | 8 | C | NOVOLOG | INSULIN ASPART | 1 | Subcutaneous | 16 UNITS, QD | U | 0 | QD | ||||||||
| 115861303 | 11586130 | 9 | C | METOPROLOL. | METOPROLOL | 1 | Oral | 100 MG, BID | U | 0 | 100 | MG | |||||||
| 115861303 | 11586130 | 10 | C | LASIX | FUROSEMIDE | 1 | UNK | U | 0 | ||||||||||
| 115861303 | 11586130 | 11 | C | IMDUR | ISOSORBIDE MONONITRATE | 1 | Oral | 60 UNITS, QD | U | 0 | QD | ||||||||
| 115861303 | 11586130 | 12 | C | DILANTIN | PHENYTOIN | 1 | Oral | 50 MG, QD | U | 0 | 50 | MG | QD | ||||||
| 115861303 | 11586130 | 13 | C | GEMFIBROZIL. | GEMFIBROZIL | 1 | U | 0 | |||||||||||
| 115861303 | 11586130 | 14 | C | FENOFIBRATE. | FENOFIBRATE | 1 | Oral | 54 MG, QD | 38070 | MG | U | 0 | 54 | MG | QD | ||||
| 115861303 | 11586130 | 15 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 40 MG, QD | U | 0 | 40 | MG | QD | ||||||
| 115861303 | 11586130 | 16 | C | VITAMIN E | .ALPHA.-TOCOPHEROL | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 115861303 | 11586130 | 17 | C | Omega 3-6-9 | FISH OIL | 1 | Oral | 1 TABLET, QD | U | 0 | TABLET | QD | |||||||
| 115861303 | 11586130 | 18 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG, QD | 0 | 81 | MG | QD | |||||||
| 115861303 | 11586130 | 19 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | 6.25 MG, BID | 1037.5 | MG | 0 | 6.25 | MG | ||||||
| 115861303 | 11586130 | 20 | C | CARVEDILOL. | CARVEDILOL | 1 | 25 MG, BID | 1037.5 | MG | 0 | 25 | MG | |||||||
| 115861303 | 11586130 | 21 | C | DEMADEX | TORSEMIDE | 1 | Oral | 20 MG, QD | 559.955017 | MG | 0 | 20 | MG | QD | |||||
| 115861303 | 11586130 | 22 | C | DEXILANT | DEXLANSOPRAZOLE | 1 | Oral | 60 MG, QD | 0 | 60 | MG | QD | |||||||
| 115861303 | 11586130 | 23 | C | DOXAZOSIN MESYLATE. | DOXAZOSIN MESYLATE | 1 | Oral | 4 MG, QHS | 331.955994 | MG | 0 | 4 | MG | QD | |||||
| 115861303 | 11586130 | 24 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | Oral | 4 MG, BID | 0 | 4 | MG | ||||||||
| 115861303 | 11586130 | 25 | C | MINOXIDIL. | MINOXIDIL | 1 | Oral | 5 MG, BID | 0 | 5 | MG | ||||||||
| 115861303 | 11586130 | 26 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | Sublingual | 0.4 MG, PRN | 0 | .4 | MG | ||||||||
| 115861303 | 11586130 | 27 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 10 MG, QD | 0 | 10 | MG | QD | |||||||
| 115861303 | 11586130 | 28 | C | SUCRALFATE. | SUCRALFATE | 1 | Oral | 1 G, QD | 0 | 1 | G | QD | |||||||
| 115861303 | 11586130 | 29 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | 50000 DF, EVERY WEEK | 0 | 50000 | DF | ||||||||
| 115861303 | 11586130 | 30 | C | PHENYTOIN SODIUM. | PHENYTOIN SODIUM | 1 | Oral | 50 MG, QD | 0 | 50 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115861303 | 11586130 | 1 | Type IIa hyperlipidaemia |
| 115861303 | 11586130 | 2 | Dyslipidaemia |
| 115861303 | 11586130 | 3 | Coronary artery disease |
| 115861303 | 11586130 | 4 | Product used for unknown indication |
| 115861303 | 11586130 | 5 | Product used for unknown indication |
| 115861303 | 11586130 | 6 | Product used for unknown indication |
| 115861303 | 11586130 | 7 | Product used for unknown indication |
| 115861303 | 11586130 | 8 | Diabetes mellitus |
| 115861303 | 11586130 | 9 | Coronary artery disease |
| 115861303 | 11586130 | 10 | Product used for unknown indication |
| 115861303 | 11586130 | 11 | Product used for unknown indication |
| 115861303 | 11586130 | 12 | Seizure |
| 115861303 | 11586130 | 13 | Product used for unknown indication |
| 115861303 | 11586130 | 14 | Dyslipidaemia |
| 115861303 | 11586130 | 15 | Gastrooesophageal reflux disease |
| 115861303 | 11586130 | 16 | Supplementation therapy |
| 115861303 | 11586130 | 17 | Supplementation therapy |
| 115861303 | 11586130 | 18 | Coronary artery disease |
| 115861303 | 11586130 | 19 | Coronary artery disease |
| 115861303 | 11586130 | 21 | Hypertension |
| 115861303 | 11586130 | 22 | Gastrooesophageal reflux disease |
| 115861303 | 11586130 | 23 | Hypertension |
| 115861303 | 11586130 | 24 | Diabetes mellitus |
| 115861303 | 11586130 | 25 | Hypertension |
| 115861303 | 11586130 | 26 | Coronary artery disease |
| 115861303 | 11586130 | 27 | Hypertension |
| 115861303 | 11586130 | 28 | Gastrooesophageal reflux disease |
| 115861303 | 11586130 | 29 | Supplementation therapy |
| 115861303 | 11586130 | 30 | Seizure |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115861303 | 11586130 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115861303 | 11586130 | Angina pectoris | |
| 115861303 | 11586130 | Asthenia | |
| 115861303 | 11586130 | Dizziness | |
| 115861303 | 11586130 | Headache | |
| 115861303 | 11586130 | Hyperhidrosis | |
| 115861303 | 11586130 | Syncope | |
| 115861303 | 11586130 | Therapy cessation | |
| 115861303 | 11586130 | Vitamin D decreased | |
| 115861303 | 11586130 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 115861303 | 11586130 | 1 | 20140405 | 20151101 | 0 | |
| 115861303 | 11586130 | 2 | 20140314 | 20150901 | 0 | |
| 115861303 | 11586130 | 3 | 20120209 | 20150901 | 0 | |
| 115861303 | 11586130 | 6 | 20140408 | 0 | ||
| 115861303 | 11586130 | 8 | 20150119 | 0 | ||
| 115861303 | 11586130 | 9 | 2014 | 20150204 | 0 | |
| 115861303 | 11586130 | 11 | 20111030 | 0 | ||
| 115861303 | 11586130 | 12 | 20140702 | 0 | ||
| 115861303 | 11586130 | 14 | 20130214 | 20150119 | 0 | |
| 115861303 | 11586130 | 15 | 20150218 | 0 | ||
| 115861303 | 11586130 | 16 | 20150119 | 0 | ||
| 115861303 | 11586130 | 17 | 20140411 | 20150218 | 0 | |
| 115861303 | 11586130 | 18 | 20120209 | 0 | ||
| 115861303 | 11586130 | 19 | 20140411 | 20140715 | 0 | |
| 115861303 | 11586130 | 20 | 20140716 | 0 | ||
| 115861303 | 11586130 | 21 | 20140605 | 20151102 | 0 | |
| 115861303 | 11586130 | 22 | 2014 | 20150218 | 0 | |
| 115861303 | 11586130 | 23 | 20140411 | 20150218 | 0 | |
| 115861303 | 11586130 | 24 | 20140716 | 0 | ||
| 115861303 | 11586130 | 25 | 20140712 | 0 | ||
| 115861303 | 11586130 | 26 | 20080331 | 0 | ||
| 115861303 | 11586130 | 27 | 20150119 | 20151026 | 0 | |
| 115861303 | 11586130 | 28 | 20150119 | 0 | ||
| 115861303 | 11586130 | 29 | 20150119 | 0 | ||
| 115861303 | 11586130 | 30 | 20140702 | 20150218 | 0 |